natgillin/translations-raw huggingface dataset:
Date of last renewal: 18 March 2007 
Datum zadnjega podaljšanja dovoljenja za promet: 18. marec 2007
Ensure that you only inject the amount as instructed by your doctor or nurse. 
Prepričajte se, da ste si vbrizgali samo odmerek, ki sta vam ga predpisala zdravnik ali medicinska sestra.
Increases in serum chemistry values including creatinine and potassium have been observed (see section 4.4). 
Opazili so tudi, da se serumske biokemične vrednosti, vključno s kreatininom in kalijem, med zdravljenjem z Dynepom zvečajo (glejte poglavje 4.4).
Dynepo is provided with a needle guard for your protection and you will be shown how to use this by your doctor or nurse. 
Zdravilo Dynepo dobite skupaj z zaščitnim pokrovčkom za injekcijsko iglo, zdravnik ali sestra pa vam bosta pokazala, kako ga uporabljati.
Dynepo 1,000 IU/0.5 ml solution for injection in a pre-filled syringe Dynepo 2,000 IU/0.5ml solution for injection in a pre-filled syringe Dynepo 3,000 IU/0.3ml solution for injection in a pre-filled syringe Dynepo 4,000 IU/0.4ml solution for injection in a pre-filled syringe Dynepo 5,000 IU/0.5 ml solution for injection in a pre-filled syringe Dynepo 6,000 IU/0.3 ml solution for injection in a pre-filled syringe Dynepo 8,000 IU/0.4 ml solution for injection in a pre-filled syringe Dynepo 10,000 IU/0.5ml solution for injection in a pre-filled syringe Epoetin delta 
Dynepo 1.000 i.e./0,5 ml raztopine za injiciranje v napolnjeni injekcijski brizgi Dynepo 2.000 i.e./0,5 ml raztopine za injiciranje v napolnjeni injekcijski brizgi Dynepo 3.000 i.e./0,3 ml raztopine za injiciranje v napolnjeni injekcijski brizgi Dynepo 4.000 i.e./0,4 ml raztopine za injiciranje v napolnjeni injekcijski brizgi Dynepo 5.000 i.e./0,5 ml raztopine za injiciranje v napolnjeni injekcijski brizgi Dynepo 6.000 i.e./0,3 ml raztopine za injiciranje v napolnjeni injekcijski brizgi Dynepo 8.000 i.e./0,4 ml raztopine za injiciranje v napolnjeni injekcijski brizgi Dynepo 10.000 i.e./0,5 ml raztopine za injiciranje v napolnjeni injekcijski brizgi
If it is cloudy or there are particles in it, you 
Če je zdravilo motno ali če vsebuje
There is therefore consistent evidence to suggest that there may be significant harm to patients with cancer who are treated with recombinant human erythropoietin. 
To pomeni, da obstajajo trdni dokazi, ki kažejo, da je lahko zdravljenje z rekombinantnim humanim eritropoetinom zelo škodljivo za bolnike z rakom.
Dynepo is a clear, colourless and waterlike solution for injection containing epoetin delta. 
Dynepo je bistra, brezbarvna, vodi podobna raztopina za injiciranje, ki vsebuje epoetin delta.
Animal studies conducted with both Dynepo and epoetin alfa in pregnant female rats and rabbits did not show any teratogenic effect, but indicated class-related reversible effects on growth and haematopoiesis in the offspring. 
Pri študijah na živalih z zdravilom Dynepo in epoetinom na brejih samicah podgan in kuncev niso ugotovili nobenih teratogenih učinkov, je pa prišlo do negativnih učinkov pri rasti in razvoju hematopoetskih celic pri potomcih.
In the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls. 
V odprti študiji ni bilo razlik med celokupnim preživetjem med bolniki, ki so prejemali rekombinantni humanim eritropoetin, in kontrolno skupino.
Store in a refrigerator (2 C - 8 C). 
Shranjujte v hladilniku (2 C - 8 C).
No accumulation of epoetin delta was observed after repeated intravenous administration three times weekly. 
Po ponavljajoči se intravenski uporabi trikrat na teden niso opazili kopičenja epoetina delta.
Polycythaemia Thrombocytosis 
policitemija, trombocitoza
Your doctor should maintain your haemoglobin level within the target range of 10 to 12 g/dl. 
Vaš zdravnik mora pri vas ohranjati raven hemoglobina v ciljnem območju od 10 do 12 g/dl.
Your doctor or nurse will tell you how much Dynepo you need and how frequently it should be injected. 
Zdravnik ali medicinska sestra vam bosta povedala, kakšen odmerek zdravila potrebujete in kako
Dose should be increased by 25 % - 50 % if: - Haemoglobin falls below < 10 g/dl and - The rate of increase of haemoglobin is below 0.7 g/dl in any 4 week period. 
Odmerek je treba zvečati za 25% - 50%, če: - se koncentracija hemoglobina zmanjša pod <10 g/dl in - hemoglobin v 4 tednih poraste za manj kot 0,7 g/dl.
Survival outcomes and tumour progression in cancer patients that are being treated with Dynepo for anaemia associated with chronic renal failure have not been investigated. 
Preživetje in napredovanje tumorja pri bolnikih z rakom, ki se zdravijo z Dynepom zaradi anemije, ki je povezana s kronično ledvično odpovedjo, nista bila raziskana.
The extent to which the outcomes observed in the clinical studies discussed above may apply to this patient population is unclear, specifically considering that the dosages administered in the renal indication are lower than in the cancer indication. 
V kakšni meri rezultati iz zgoraj opisanih kliničnih preskušanj veljajo za to populacijo bolnikov ni jasno, zlasti če upoštevamo, da so odmerki, ki se uporabljajo za ledvično indikacijo, nižji od odmerkov, ki so indicirani pri raku.
You will be monitored closely to ensure the lowest dose of Dynepo is used to provide adequate control of your symptoms of anaemia. 
Natančno vas bodo spremljali, da bodo zagotovili uporabo najmanjšega odmerka Dynepa, ki omogoča zadosten nadzor simptomov anemije.
In clinical trials, an increased risk of death and serious cardiovascular events was observed when erythropoiesis stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dL (7.5 mmol/l). 
V kliničnih preskušanjih so ugotovili povečano tveganje za smrt in resne srčno-žilne dogodke, če je bila ciljna raven hemoglobina, dosežena z zdravili za stimulacijo eritropoeze (ESA - erythropoiesis stimulating agent), nad 12 g/dl (7,5 mmol/l).
This does not affect normal operation of the syringe and the syringe can be rotated in the device. 
To ne vpliva na uporabo brizge, brizgo pa lahko v pripravi vrtite.
Clinical experience with epoetins suggest hypertension and thrombosis risk may be reduced by titrating the dose to maintain haemoglobin levels between 10 to 12 g/dl. 
Klinične raziskave z epoetinom kažejo, da je tveganje v zvezi s zvišanim krvnim tlakom in trombozo mogoče zmanjšati s titracijo odmerka, da raven hemoglobina ohranimo med 10 in 12 g/dl.
If blood pressure values remain high, a transient interruption of Dynepo therapy may be required. 
Če krvni tlak ostane zvišan, utegne biti potrebna začasna prekinitev zdravljenja z
Do not shake the syringe before use. 
Brizge pred uporabo ne smete pretresati.
- The active substance is epoetin delta, 0.5 ml of the solution containing 1,000 IU (International Units) (2,000 IU/ml), 0.5 ml of the solution containing 2,000 IU (4,000 IU/ml), 0.3 ml of the solution containing 3,000 IU (10,000 IU/ml), 0.4ml of the solution containing 4,000 IU (10,000 IU/ml), 0.5 ml of the solution containing 5,000 IU (10,000 IU/ml), 0.3 ml of the solution containing 6,000 IU (20,000 IU/ml), 0.4 ml of the solution containing 8,000 IU (20,000 IU/ml), or 0.5 ml of the solution containing 10,000 IU/ml (20,000 IU/ml) of epoetin 
Zdravilna učinkovina je epoetin delta; 0,5 ml raztopine, vsebuje 1.000 i.e. (mednarodnih enot) (2.000 i.e./ml), 0,5 ml raztopine, vsebuje 2.000 i.e. (4.000 i.e./ml), 0,3 ml raztopine, ki vsebuje 3.000 i.e. (10.000 i.e./ml), 0,4 ml raztopine, vsebuje 4.000 i.e. (10.000 i.e./ml), 0,5 ml raztopine, vsebuje 5.000 i.e. (10.000 i.e./ml), 0,3 ml raztopine, vsebuje 6.000 i.e. (20.000 i.e./ml), 0,4 ml raztopine, vsebuje 8.000 i.e. (20.000 i.e./ml), ali 0,5 ml raztopine, vsebuje 10.000 i.e. (20.000 i.e./ml) epoetina delta.
Patients on Dynepo therapy can experience increase in blood pressure or aggravation of existing hypertension. 
Bolnikom, ki dobivajo Dynepo, se lahko zviša krvni tlak ali se jim poslabša obstoječa hipertenzija.
To give yourself a subcutaneous injection you will need a new pre-filled syringe of Dynepo with needle guard. 
Da si boste lahko subkutano injicirali zdravilo, boste potrebovali novo, z zdravilom Dynepo napolnjeno injekcijsko brizgo z zaščitnim pokrovčkom za iglo.
Depress the plunger slowly and evenly while holding the syringe barrel, always keeping your skin pinched. 
Med držanjem brizge počasi in enakomerno pritiskajte na bat, pri tem pa držite kožno gubo.
The haemoglobin level should be determined once a week until it has stabilised in the suggested target range and the maintenance dose has been established. 
Koncentracijo hemoglobina je treba določiti vsak teden, dokler se ne ustali v priporočenem ciljnem območju in ni določen vzdrževalni odmerek.
The frequency of adverse events that were experienced during Dynepo therapy is tabulated below. 
Pogostost neželenih učinkov, ki so se pojavili pri bolnikih med zdravljenjem z zdravilom Dynepo, je navedena spodaj.
Check the expiry date on the pre-filled syringe label (EXP:). 
Preverite datum izteka roka uporabnosti na napolnjeni injekcijski brizgi (EXP.).
Since many compounds are excreted in human milk, caution should be advised when Dynepo is administered to breast-feeding women. 
Številne spojine se izločajo v materinem mleku, zato je treba Dynepo pri doječih ženskah uporabljati previdno.
Once hypertension is controlled with more intensified therapy, Dynepo therapy should be re-started at a reduced dose. 
Ko je hipertenzija z intenzivirano terapijo urejena, je mogoče zdravljenje z Dynepom začeti znova, z
Epoetin delta is a human erythropoietin made by a technology process called gene-activation, which uses a human cell line. 
Epoetin delta je človeški eritropoetin, pridobljen iz linije človeških celic s posebnim tehnološkim postopkom, gensko aktivacijo.
An increased relative risk of thromboembolic events (RR 1.67, 95% CI: 1.35, 2.06, 35 trials and 6769 patients) was observed in patients treated with recombinant human erythropoietin. 
Pri bolnikih, ki so se zdravili z rekombinantnim humanim eritropoetinom, so ugotovili zvišano relativno tveganje za tromboembolične dogodke (RR 1,67; 95-% IZ: 1,35, 2,06, 35 preskušanj in 6.769 bolnikov).
Occasionally, your individual haemoglobin values may be above and below this recommended target level. 
Občasno so lahko posamezne vrednosti hemoglobina nad ali pod to priporočeno ciljno koncentracijo.
In addition, a reduction of the administered dose of Dynepo needs to be considered. 
Razmisliti je treba tudi o zmanjšanju odmerka Dynepa.
• Haemoglobinopathies such as thalassaemia or sickle cell anaemia 
• hemoglobinopatije, npr. talasemija ali anemija s srpastimi celicami
Hold the syringe assembly by the sides of the device and gently remove the plastic cover and rubber guard from the needle without twisting. 
Rahlo držite injekcijsko brizgo na obeh straneh priprave in odstranite plastičen pokrovček in gumijasto zaščito z igle ter pazite, da je ne zvijete.
The manufacturer is Shire Human Genetic Therapies AB, Åldermansgatan 2, P.O. 
Izdelovalec je: Shire Human Genetic Therapies AB Åldermansgatan 2, P.O. Box 1117, SE-221 04
Pharmacotherapeutic group: Antianaemic - ATC code: B03XA. 
Farmakoterapevtska skupina: zdravila za zdravljenje slabokrvnosti - oznaka ATC: B03XA.
It may be used in patients on dialysis and in patients not on dialysis. 
Uporablja se lahko pri bolnikih, ki so na dializi, in pri tistih,
Available in packs of 6 pre-filled syringes. 
Na voljo so pakiranja s 6 napolnjenimi injekcijskimi brizgami.
In the iron-replete patient with an inadequate response to Dynepo therapy, the following conditions should be evaluated and treated, if appropriated: 
Pri bolnikih, ki imajo zaloge železa napolnjene, a se na zdravljenje z Dynepom ne odzovejo ustrezno, je treba raziskati možnost naslednjih bolezni in jih po potrebi zdraviti:
A rise in haemoglobin of greater than 2 g/dL (1.25 mmol/l) over a four week period should be avoided. 
Izogniti se moramo zvišanju ravni hemoglobina za več kot 2 g/dl (1,25 mmol/l) v štirih tednih.
Peak serum concentrations for subcutaneously administered epoetin delta occur between 8 and 36 hours following injection. 
Po subkutani uporabi doseže epoetin delta največjo koncentracijo v serumu od 8 do 36 ur po injekciji.
Prefilled Type I glass syringe with bromobutyl rubber stopper, 27 gauge stainless steel needle with rigid natural rubber and polystyrene needle shield, polystyrene plunger rod and a needle safety guard. 
Napolnjene injekcijske brizge iz stekla tipa I z gumijastim zamaškom iz bromobutila, igla dimenzije 27 (gauge) iz nerjavnega jekla, ki je zaščitena z naravno trdo gumo in polistirenom, bat iz polistirena in zaščitni pokrovček za iglo.
Do not use after the expiry date stated on the carton and on the label of the syringe after “EXP”. 
Zdravila Dynepo ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini in na nalepki brizge poleg oznake »EXP«.
Do not warm Dynepo in any other way (for example, do not warm it in a microwave or in hot water). 
Injekcijske brizge z zdravilom Dynepo ne segrevajte na noben drug način (npr. ne segrevajte v
Subcutaneous administration results in a similar pattern of erythropoietic stimulation as after intravenous administration. 
Subkutana uporaba vpliva na stimulacijo eritropoeze podobno kot intravenska.
If you are not sure about giving the injection or you have any questions, please ask your doctor or nurse for help. 
Če niste prepričani glede samoinjiciranja zdravila ali če imate kakršno koli vprašanje, se posvetujte z zdravnikom ali farmacevtom.
Packs of 6 pre-filled syringes are available. 
Na voljo so škatle s šestimi napolnjenimi injekcijskimi brizgami.
Dynepo is not approved for use in cancer patients. 
Zdravilo Dynepo ni odobreno za zdravljenje bolnikov, obolelih za rakom.
The maintenance dose will be then decided by your doctor to maintain the level of your haemoglobin within the target range. 
Vzdrževalni odmerek bo zdravnik nato določil tako, da bo vašo koncentracijo hemoglobina vzdrževal
Information on how to give yourself an injection of Dynepo This section contains information on how to give yourself an injection of Dynepo. 
Podatki o tem, kako si sami injicirate zdravilo Dynepo V naslednjih navodilih je razloženo, kako si sami injicirate zdravilo Dynepo.
Before you inject Dynepo you must do the following: 
Pred injiciranjem zdravila storite naslednje:
It is recommended that a complete blood count and platelet count is performed regularly. 
Priporočljivo je redno spremljanje celotne krvne slike in števila trombocitov.
Your Dynepo syringe is provided with a needle guard to prevent needle stick injuries after use, so no special disposal precautions are required. 
Injekcijska brizga Dynepo ima varnostni zamašek, ki preprečuje vbode po uporabi, tako da za odlaganje igel niso potrebni posebni previdnostni ukrepi.
The 5 day period must end before the expiry date stated on the carton and label of the syringe after ‘EXP'. 
Obdobje petih dni ne sme preseči roka uporabnosti, ki je naveden na pretisnem omotu in injekcijski brizgi za oznako 'EXP'.
Pull straight. 
PRETISNI OMOTI
Do not use it if the date has passed 
Zdravila ne smete uporabljati če je datum že pretekel zadnji dan navedenega meseca.
Excipients: sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, sodium chloride, polysorbate 20 and water for injections. 
Pomožne snovi: natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat heptahidrat, natrijev klorid, polisorbat 20 in voda za injekcije.
You may notice a small air bubble in the pre-filled syringe. 
V injekcijski brizgi lahko opazite majhen zračni mehurček.
During the clinical trials, there were no indications of development of neutralising antibodies to epoetin delta in humans based on the clinical response. 
V kliničnih preskušanjih pri ljudeh glede na klinični odziv ni bilo znakov razvoja nevtralizirajočih protiteles proti epoetinu delta.
The syringe is pre-assembled with a needle safety guard to prevent needle stick injury. 
Injekcijska brizga je opremljena z zaščitnim pokrovčkom za iglo, ki preprečuje vbode z iglo.
The solution is clear, colourless and waterlike with no visible particles. 
Raztopina ie bistra, brezbarvna, podobna vodi in ne vsebuje vidnih delcev.
Overall survival outcome in the trials could not be satisfactorily explained by differences in the incidence of thrombosis and related complications between those given recombinant human erythropoietin and those in the control group. 
Izida za celokupno preživetje v preskušanjih se med tistimi, ki so prejemali rekombinantni humani eritropoetin, in tistimi v kontrolni skupini, ni dalo zadovoljivo razložiti s pomočjo razlik v incidenci tromboze in sorodnih
The revised expiry date for storage at below 25oC must not exceed the expiry date set in accordance with the 24 month shelf-life. 
Spremenjeni rok uporabnosti za shranjevanje brizg izven hladilnika, pri temperaturi, nižji od 25°C, ne sme preseči roka uporabnosti, ki naveden na ovojnini.
There may be also changes in the chemistry of your blood, including increase of creatinine, potassium levels. 
Spremenijo se lahko biokemične vrednosti v krvi, z zvečanjem koncentracije kreatinina in kalija vred.
During haemodialysis, patients treated with Dynepo may require increased anticoagulation treatment to prevent clotting of the arterio-venous shunt. 
Bolniki, zdravljeni z Dynepom, utegnejo med hemodializo potrebovati več antikoagulantov za preprečitev zapore arteriovenskega šanta.
If you take more Dynepo than you should 
Če ste si injicirali več Dynepa, kot bi smeli
Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. 
Zdravilo Dynepo je indicirano za zdravljenje simptomatske anemije, ki je povezana s kronično ledvično odpovedjo pri odraslih bolnikih.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH 
IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE (UČINKOVIN) IN METNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA
Keep the container in the outer carton in order to protect from light. 
Vsebnik shranjujte v zunanji ovojnini, za zaščito pred svetlobo.
It is important that you do not try to give yourself the injection unless you have received special training from your doctor or nurse. 
Ne poskušajte si injicirati zdravila, če vas o tem nista poučila vaš zdravnik ali medicinska sestra.
Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham, Basingstoke Hampshire, RG24 8EP United Kingdom 
Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham, Basingstoke Hampshire RG24 8EP Velika Britanija
Patients should be monitored closely to ensure that the lowest approved dose of Dynepo is used to provide adequate control of the symptoms of anaemia. 
Bolnike je treba pozorno spremljati, da lahko simptome anemije ustrezno nadzorujemo s čim manjšim odobrenim odmerkom zdravila Dynepo.
- if you are on haemodialysis you may experience blockage of the dialysis tubes as your anaemia improves (increase in red blood cells). 
- Če ste na hemodializi, se lahko z izboljšanjem anemije (zvečanjem števila eritrocitov) pojavi mašitev dializnih cevk.
Dynepo is not indicated for the management of anaemia associated with cancer. 
Uporaba zdravila Dynepo ni predvidena za zdravljenje anemije, ki je povezana z rakom..
Your doctor will measure your blood iron level during treatment with Dynepo and may give you iron supplements. 
Zdravnik bo med zdravljenjem z Dynepom nadzoroval koncentracijo železa v vaši krvi in vam morda
An increase in the dose of the anticoagulation treatment is frequently required to prevent the blockage occurring. 
Za preprečitev takšne zamašitve je pogosto treba zvečati odmerek antikoagulantnih zdravil.
Epoetin delta is produced in human cells (HT-1080) by gene-activation technology. 
Epoetin delta je pridobljen iz človeških celic (HT-1080) s posebnim tehnološkim postopkom - gensko Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Your doctor will closely monitor your haemoglobin concentration level to keep it within the target range of 10 to 12 g/dl and may therefore need to change your dosage of Dynepo accordingly. 
Pri uporabi zdravila Dynepo bodite posebno pozorni Zdravnik bo pri vas natančno spremljal raven hemoglobina, da bo ostala v ciljnem območju od 10 do 12 g/dl, zato bo morda moral zaradi tega spremeniti odmerjanje Dynepa.
Pain Injection site reaction (e.g. pain, haemorrhage) Flu-syndrome 
driska navzea pruritus bolečine reakcija na mestu injiciranja (npr. bolečine, krvavitev) gripi podoben sindrom
If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice. 
Če imate kakršno koli težavo, ne oklevajte in se o tem posvetujte z zdravnikom ali z medicinsko
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dL (6.2 mmol/l) to 12g/dL (7.5mmol/l). 
Razlike v ravni hemoglobina se urejajo z uravnavanjem odmerkov, pri čemer se upošteva, da je ciljno območje ravni hemoglobina od 10 g/dl (6,2 mmol/l) do 12 g/dl.
Dynepo should be administered either subcutaneously or intravenously in order to increase haemoglobin to not greater than 12 g/dL (7.5 mmol/L). 
Zdravilo Dynepo se lahko daje subkutano ali intravensko, da se zviša raven hemoglobina do največ 12 g/dl (7,5 mmol/l).
The usual starting dose is 50 IU/kg three times a week if administered intravenously or 50 IU/kg twice a week if administered subcutaneously. 
Pri intravenski uporabi je običajni začetni odmerek 50 i.e./kg trikrat na teden, pri subkutani pa 50 i.e./kg dvakrat na teden.
• The top of your thighs; and 
• zgornji del stegen in
Survival and tumour progression have been examined in five large controlled studies of epoetin alfa, beta and darbepoetin alfa involving a total of 2,833 patients, of which four were double-blind placebocontrolled studies and one was an open-label study. 
V petih velikih, kontroliranih študijah z epoetinom alfa, beta in darbepoetinom alfa so preiskovali preživetje in napredovanje tumorja.
Caution should be exercised when prescribing to pregnant women. 
Morebitno tveganje za ljudi ni znano, moramo pa biti previdni pri predpisovanju zdravila nosečnicam.
Store in a refrigerator (2oC to 8oC). 
Shranjujte v hladilniku (2°C - 8°C).
Your dose of Dynepo may vary depending on your weight and on your response to the treatment. 
Odmerek zdravila je odvisen od vaše telesne mase in od tega, kako prenašate zdravilo.
Keep syringes in the outer carton to protect from light. 
Brizge shranjujte v zunanji ovojnini, za zagotovitev zaščite pred svetlobo.
Inform your doctor if you are pregnant or breast-feeding or think you might be pregnant. 
Če ste noseči, domnevate, da ste noseči, ali če dojite, morate to povedati zdravniku.
Serum chemistry values including creatinine and potassium should be monitored regularly during Dynepo therapy. 
Med zdravljenjem z Dynepom je treba redno kontrolirati biokemične vrednosti v serumu, vključno s kreatininom in kalijem.
If severe polycythaemia occurs, conventional methods (phlebotomy) may be indicated to decrease the haemoglobin level. 
Če se pojavi huda policitemija, so za zmanjšanje koncentracije hemoglobina lahko indicirani
Sufficient time should be allowed to determine a patient's responsiveness to a dosage of Dynepo before adjusting the dose. 
Pred prilagoditvijo odmerka je treba počakati dovolj dolgo, da je mogoče ugotoviti bolnikov odziv na zdravljenje z Dynepom.
- 1,000 IU in 0.5 ml 
Odmerek raztopine je: - 1.000 i.e. v 0,5 ml
Therefore, in patients treated with Dynepo, special care should be taken to monitor closely and control blood pressure. 
Zato je treba pri bolnikih, ki se zdravijo z Dynepom, krvni tlak posebej natančno spremljati in uravnavati.
Exposure to erythropoietin following administration of epoetin delta increases proportionately in patients given intravenous doses of 50 IU/kg to 300 IU/kg. 
Po intravenski uporabi epoetina delta v odmerkih od 50 i.e./kg do 300 i.e./kg se izpostavljenost eritropoetinu pri bolnikih proporcionalno zvečuje.
In case of its use during pregnancy, concomitant iron substitution should be considered in the mother. 
Pri uporabi med nosečnostjo je treba pretehtati